EUVIMEDEUVIMED entdecken
Crossref

Leucine-rich α2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis

Minoru Fujimoto iD, Yuji Hosono, Satoshi Serada, Yuji Suzuki, Tomoharu Ohkawara, Okinori Murata, Ayumi Quick, Katuya Suzuki, Yuko Kaneko, Tsutomu Takeuchi, Tetsuji Naka

Modern Rheumatology · 2024

DOI: 10.1093/mr/road112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Minoru Fujimoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Rheumatology, Department of Internal Medicine, School of Medicine Iwate Medical University, Yahaba-cho, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Biomarkers. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is a systemic autoimmune disease that induces irreversible joint destruction and leads to disability, comorbidities, and increased mortality [1]. Recently, the implementation of treat-to-target strategy and availability of disease-modifying anti-rheumatic drugs, including biologic therapies, have revolutionized the management of RA. Nevertheless, given that the treatment responses and disease course vary between patients, periodic evaluation of disease activity during therapy is essential. Measurements of acute-phase reactants, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), have been traditionally used as objective biomarkers for RA. However, treatment with anti-cytokine biologics, especially interleukin (IL)-6-targeting therapies, can downregulate CRP and ESR levels directly, often resulting in normalization of these biomarkers despite having active disease [2]. These alterations in biomarker levels during therapy can complicate the accurate assessment of disease activity and lead to its potential underestimation. As such, alternative biomarkers that can assess RA disease activity despite the influence of IL-6-targeting therapies need to be identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidBiomarkersFemaleHumansMaleMiddle AgedAdipokinesGlycoproteinsSeverity of Illness Index

Stichwörter der Autor:innen

Biomarkerdisease activityleucine-rich α2-glycoproteinrheumatoid arthritis

Substanzen

AdipokinesBiomarkersGlycoproteinsLRG1 protein, human

Autor:innen und Institutionen

  • Division of Allergy and Rheumatology, Department of Internal Medicine, School of Medicine Iwate Medical University, Yahaba-cho, Japan.
  • Institute for Biomedical Sciences Molecular Pathophysiology, Iwate Medical University, Yahaba-cho, Japan.
  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Minoru Fujimoto

Zitieren

APA

Fujimoto, M., Hosono, Y., Serada, S., Suzuki, Y., Ohkawara, T., Murata, O., Quick, A., Suzuki, K., Kaneko, Y., Takeuchi, T., & Naka, T. (2024). Leucine-rich α2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis. Modern Rheumatology. https://doi.org/10.1093/mr/road112

Vancouver

Fujimoto M, Hosono Y, Serada S, Suzuki Y, Ohkawara T, Murata O, et al. Leucine-rich α2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis. Modern Rheumatology. 2024. doi:10.1093/mr/road112

BibTeX
@article{Fujimoto2024,
  author = {Fujimoto, Minoru and Hosono, Yuji and Serada, Satoshi and Suzuki, Yuji and Ohkawara, Tomoharu and Murata, Okinori and Quick, Ayumi and Suzuki, Katuya and Kaneko, Yuko and Takeuchi, Tsutomu and Naka, Tetsuji},
  title = {Leucine-rich α2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/road112}
}
Kostenlos starten →